The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Evolving combination and targeted therapies in myeloproliferative neoplasms
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses how treatment of myeloproliferative neoplasms (MPNs) may evolve over the next three to five years. He highlights the growing role of combination therapies and targeted approaches, including therapies directed against specific molecular alterations, with the potential to tailor treatment more closely to individual disease biology. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
